PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.86%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-40.21%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
6.04%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
6.04%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-40.21%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-66.22%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-6.04%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-333.64%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-65.74%
Pre-tax income decline while RVPH shows 5.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
-65.74%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-47.67%
EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-53.82%
Diluted EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
12.14%
Share count reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.
7.50%
Diluted share reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.